Duo Fight For Fingolimod Share In Canada
Patent-Infringement Actions Were Discontinued
Teva and Pharmascience are going head-to-head in a battle to capture the market for generic Gilenya fingolimod capsules in Canada.
You may also be interested in...
The first three FDA approvals for generic fingolimod generics come amid ongoing legal uncertainty over Novartis’ Gilenya blockbuster multiple sclerosis treatment.
New Sandoz chief Richard Saynor says the division is undergoing a transformation towards building a generics-focused business. Meanwhile, the company is still waiting to close the sale of its US oral-dose and dermatology operations to Aurobindo.
Difficulties around damages, fears over first-dose observations and criticism of invalidity challenges all contributed to a US district court judge issuing a preliminary injunction to stop leading generics players launching rivals to Novartis’ Gilenya fingolimod multiple sclerosis brand after the molecule patent expires in August this year.